LU91805B1 - Virus inhibitory compositions for therapeutic use in vivo - Google Patents

Virus inhibitory compositions for therapeutic use in vivo

Info

Publication number
LU91805B1
LU91805B1 LU91805A LU91805A LU91805B1 LU 91805 B1 LU91805 B1 LU 91805B1 LU 91805 A LU91805 A LU 91805A LU 91805 A LU91805 A LU 91805A LU 91805 B1 LU91805 B1 LU 91805B1
Authority
LU
Luxembourg
Prior art keywords
vivo
therapeutic use
inhibitory compositions
virus inhibitory
virus
Prior art date
Application number
LU91805A
Other languages
French (fr)
Inventor
Christine Coppens
Original Assignee
Cesa Alliance Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91805(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cesa Alliance Sa filed Critical Cesa Alliance Sa
Application granted granted Critical
Publication of LU91805B1 publication Critical patent/LU91805B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
LU91805A 2010-03-26 2011-03-28 Virus inhibitory compositions for therapeutic use in vivo LU91805B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10157930A EP2368547B1 (en) 2010-03-26 2010-03-26 Antiviral compositions comprising geraniol and carvone

Publications (1)

Publication Number Publication Date
LU91805B1 true LU91805B1 (en) 2011-09-26

Family

ID=42102951

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91805A LU91805B1 (en) 2010-03-26 2011-03-28 Virus inhibitory compositions for therapeutic use in vivo

Country Status (35)

Country Link
US (2) US8980945B2 (en)
EP (2) EP2368547B1 (en)
JP (1) JP5342085B2 (en)
KR (1) KR101340260B1 (en)
CN (1) CN102946876B (en)
AU (1) AU2011231511B2 (en)
BR (1) BR112012024260B1 (en)
CA (1) CA2790087C (en)
CL (1) CL2012002606A1 (en)
CO (1) CO6602166A2 (en)
CY (3) CY1113449T1 (en)
DK (2) DK2368547T3 (en)
EA (1) EA025278B9 (en)
ES (2) ES2392938T3 (en)
HK (1) HK1176019A1 (en)
HR (2) HRP20120964T1 (en)
HU (1) HUE026121T2 (en)
IL (1) IL222048A (en)
LU (1) LU91805B1 (en)
MA (1) MA34074B1 (en)
ME (1) ME02035B (en)
MX (1) MX346412B (en)
MY (2) MY153104A (en)
NZ (1) NZ602602A (en)
PE (2) PE20130065A1 (en)
PL (2) PL2368547T3 (en)
PT (2) PT2368547E (en)
RS (2) RS52544B (en)
SG (1) SG184039A1 (en)
SI (2) SI2368547T1 (en)
SM (2) SMT201200062B (en)
TN (2) TN2012000444A1 (en)
UA (1) UA102497C2 (en)
WO (1) WO2011117424A1 (en)
ZA (2) ZA201208116B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013064360A2 (en) 2011-11-03 2013-05-10 Unilever N.V. A personal cleaning composition
JP2015500819A (en) 2011-12-06 2015-01-08 ユニリーバー・ナームローゼ・ベンノートシヤープ Antibacterial composition
MX354483B (en) 2011-12-06 2018-03-07 Unilever Nv Antimicrobial composition.
CN104023539B (en) 2011-12-06 2021-08-13 联合利华知识产权控股有限公司 Antimicrobial compositions
IN2014MN02378A (en) * 2012-06-27 2015-08-14 Unilever Plc
RU2533254C2 (en) * 2012-12-29 2014-11-20 Федеральное государственное бюджетное учреждение научно-исследовательский институт детских инфекций Федерального медико-биологического агентства Method of treating neurological complications of varicella in children
TWI463979B (en) * 2013-04-12 2014-12-11 Nat Defense Medical Ct Use of citral for manufacturing medicament for treating focal segmental glomerulosclerosis
KR20150145314A (en) 2014-06-18 2015-12-30 원광대학교산학협력단 Antimicrobial composition comprising carvone
CN106727628A (en) * 2016-12-17 2017-05-31 郑州郑先医药科技有限公司 A kind of Western medicine compound for treating chronic diarrhea
KR101970281B1 (en) * 2017-07-28 2019-04-18 고려대학교 산학협력단 Composition for Preventing or Treating Olmesartan-Induced Intestinal Hypermotility Comprising Linalyl Acetate
CN107648488A (en) * 2017-09-29 2018-02-02 陈晓阳 A kind of pill for being used to treat chronic pharyngitis
KR102118181B1 (en) * 2018-06-12 2020-06-02 광주여자대학교 산학협력단 Antiviral composition for influenza a virus comprising plant essential oils as an active material
RU2707950C1 (en) * 2018-11-28 2019-12-02 Общество с ограниченной ответственностью "ЭРБИ" Agent for treating poultry keeping environment based on liposomes with phytocomposition with immunotropic action and selective antiseptic effect and method of using
US20200179299A1 (en) * 2018-12-07 2020-06-11 Global Biolife Inc. Composition and method of controlling infectious diseases with functional fragrances
CN110496117B (en) * 2019-09-30 2022-09-06 中国科学院微生物研究所 New application of small molecular compound in resisting African swine fever virus infection
CN111012769B (en) * 2019-12-05 2021-02-12 青海大学 Pharmaceutical composition for treating echinococcosis, pharmaceutical preparation and preparation method of emulsion
WO2021224947A1 (en) * 2020-05-02 2021-11-11 Norouzi Mehdi Formulation of acute respiratory disease control formulation
CN114716327A (en) * 2020-12-14 2022-07-08 中南民族大学 Cedrol derivative, preparation method and application thereof
CA3102947A1 (en) * 2020-12-18 2022-06-18 Skymount Medical Us Inc. Nutraceuticals useful in the treatment of coronavirus diseases
JP7133820B1 (en) * 2021-06-09 2022-09-09 塩野香料株式会社 Perfume composition for preventing coronavirus infection and binding inhibitor
CN113994963B (en) * 2021-09-26 2023-04-28 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) Bud inhibitor containing dihydrocarvyl acetate and application thereof
TWI800937B (en) * 2021-10-01 2023-05-01 奇美醫療財團法人奇美醫院 Method for treating dengue virus infection
CN117338758B (en) * 2023-12-06 2024-03-12 北京远大九和药业有限公司 Pharmaceutical composition and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5667M (en) 1966-03-10 1968-01-02
LU78955A1 (en) 1978-01-27 1979-09-06 Chimicasa Gmbh METHOD FOR INACTIVATING VIRUSES
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
KR20140103191A (en) * 2005-11-30 2014-08-25 에덴 리서치 피엘씨 Compositions and methods comprising terpenes or terpene mixtures selected from thymol, eugenol, geraniol, citral, and l-carvone
US9403126B2 (en) * 2007-01-10 2016-08-02 The Regents Of The University Of Michigan Ultrafiltration membrane, device, bioartificial organ, and related methods
KR100796312B1 (en) * 2007-05-23 2008-01-21 주식회사 바이오미스트테크놀로지 Antiseptic composition for animal based on geranial, neral and eugenol
KR100950428B1 (en) 2008-06-05 2010-04-02 주식회사 알앤엘바이오 Diarylheptanoid for viral inhibitor
KR100941595B1 (en) 2008-06-05 2010-02-11 주식회사 알앤엘바이오 Tritepenoid for viral inhibitor

Also Published As

Publication number Publication date
CN102946876A (en) 2013-02-27
BR112012024260B1 (en) 2019-12-31
PL2555763T3 (en) 2014-09-30
CN102946876B (en) 2016-04-06
MY153104A (en) 2014-12-31
CL2012002606A1 (en) 2013-10-18
EP2555763B1 (en) 2014-04-30
ME02035B (en) 2013-04-30
SG184039A1 (en) 2012-10-30
AU2011231511A1 (en) 2012-10-18
CA2790087A1 (en) 2011-09-29
PE20130065A1 (en) 2013-03-08
CO6602166A2 (en) 2013-01-18
TN2012000444A1 (en) 2014-01-30
RS53435B (en) 2014-12-31
WO2011117424A1 (en) 2011-09-29
TN2013000366A1 (en) 2015-01-20
ES2392938T3 (en) 2012-12-17
UA102497C2 (en) 2013-07-10
RS52544B (en) 2013-04-30
EP2368547A1 (en) 2011-09-28
PL2368547T3 (en) 2013-02-28
US8883859B1 (en) 2014-11-11
PE20141008A1 (en) 2014-09-20
KR101340260B1 (en) 2013-12-10
EP2555763A1 (en) 2013-02-13
AU2011231511B2 (en) 2014-03-20
JP5342085B2 (en) 2013-11-13
SMT201400104B (en) 2014-09-08
EA201270749A1 (en) 2013-03-29
JP2013523622A (en) 2013-06-17
NZ602602A (en) 2012-12-21
HRP20120964T1 (en) 2012-12-31
EP2368547B1 (en) 2012-09-12
SI2555763T1 (en) 2014-08-29
US20130225676A1 (en) 2013-08-29
PT2555763E (en) 2014-08-04
CY1115375T1 (en) 2017-01-04
CY1119841T1 (en) 2018-06-27
IL222048A (en) 2014-09-30
DK2555763T3 (en) 2014-08-04
MX2012010949A (en) 2013-01-29
HRP20140706T1 (en) 2014-09-12
HK1176019A1 (en) 2013-07-19
PT2368547E (en) 2012-11-20
MY158757A (en) 2016-11-15
KR20120128716A (en) 2012-11-27
ZA201306926B (en) 2014-04-30
BR112012024260A2 (en) 2016-07-12
EA025278B9 (en) 2017-03-31
US8980945B2 (en) 2015-03-17
HUE026121T2 (en) 2016-05-30
ES2486765T3 (en) 2014-08-19
SI2368547T1 (en) 2013-01-31
DK2368547T3 (en) 2013-01-02
MX346412B (en) 2017-03-17
MA34074B1 (en) 2013-03-05
CA2790087C (en) 2013-07-30
EA025278B1 (en) 2016-12-30
ZA201208116B (en) 2014-04-30
SMT201200062B (en) 2013-03-08
CY1113449T1 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
LU91805B1 (en) Virus inhibitory compositions for therapeutic use in vivo
SMT201700008B (en) PHARMACEUTICAL COMPOSITION
SMT201600350B (en) PHARMACEUTICAL COMPOSITIONS
SMT201500148B (en) Compositions for use in the treatment of viral infections
DK2549946T3 (en) DYNAMIC VIRTUAL ARTICULATOR
DK3023788T3 (en) Compositions of tumor-specific neoantigens for use in the treatment of tumors
BRPI1009275A2 (en) virtual object manipulation
DK3246018T3 (en) PHARMACEUTICAL COMPOSITION
EP2556430A4 (en) Virtual application extension points
BR112013011472A2 (en) Gel Composition
EE201300005A (en) Pharmaceutical composition
FR2968669B1 (en) FAT COMPOSITION
IL238107B (en) Compositions comprising masitinib for use in treatment of cancer in patient subpopulations identified using predictor factors
FR2968670B1 (en) FAT COMPOSITION
BR112012030765A2 (en) sterile liquid composition
FR2958537B1 (en) DENTAL COMPOSITION
CO6801722A2 (en) Pharmaceutical compositions
GB201011095D0 (en) Improvements in or relating to ophthalmology
ZA201209701B (en) Improvements in or relating to ophthalmology
BR112013014811A2 (en) cloth treatment composition
CR11728S (en) HAIRDRYER
BR112012022411A2 (en) articulator
FR2957252B1 (en) COSMETIC COMPOSITION
BR112013003275A2 (en) oral treatment composition
BR112012029461A2 (en) solifenacin-containing pharmaceutical composition